Sanofi-aventis Announces Second Quarter 20...( ...)

BRIDGEWATER, N.J., July 29 /PRNewswire-FirstCall/ --

                                      Change                      Change
                           Change       at              Change      at
                            on a     constant            on a    constant
                   Q2     reported   exchange          reported  exchange
                  2009     basis      rates    H1 2009   basis     rates
                 -------  ---------  --------  -------  -------   -------
    Net           euro                           euro
     sales       7,438m     +11.2%      +6.5%  14,545m    +6.7%     +3.1%
    Adjusted
     net
     income
     excluding
     selected     euro                           euro
     items       2,268m     +29.4%     +17.2%   4,446m   +22.3%    +12.8%
    Adjusted
     EPS
     excluding
     selected     euro                           euro
     items        1.74      +29.9%     +17.2%    3.41    +23.1%    +13.4%

In order to facilitate an understanding of our operational performance, we comment on our adjusted income statement excluding selected items, a non-GAAP financial measure. The 2009 first-half consolidated income statement is provided in Appendix 5, as are details of adjustments and selected items. Consolidated net income for the first half of 2009 was euro 2,637 million, versus euro 2,335 million for the first half of 2008. Consolidated earnings per share for the first half of 2009 was euro 2.02, against euro 1.78 for the first half of 2008.

Good performance(1) in the second quarter of 2009

• Strong growth from Lantus(R) (up 26.0%), Lovenox(R) (up 13.3%) and Taxotere(R) (up 10.7%). Further dynamism in the worldwide presence of Plavix(R) (up 9.6%)
  

• Growth of 18.4% for the Vaccin
  '/>"/>